Vycor Medical, Inc. (VYCO)
- Previous Close
0.0600 - Open
0.0511 - Bid 0.0510 x --
- Ask 0.0980 x --
- Day's Range
0.0511 - 0.0511 - 52 Week Range
0.0330 - 0.1280 - Volume
1,000 - Avg. Volume
6,796 - Market Cap (intraday)
1.705M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. It operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment provides devices for neurosurgery comprising ViewSite Brain Access System, a retraction and access system for brain and spine surgeries. The NovaVision segment offers non-invasive computer-based rehabilitation targeted at people who have impaired vision as a result of stroke or other brain injury. It has a license agreement which grants for the license to provide NovaVision's products and therapies to patients and professionals in Germany, Austria and Switzerland. It primarily serves hospitals and medical professionals. Vycor Medical, Inc. was founded in 2005 and is headquartered in Boca Raton, Florida. Vycor Medical, Inc. is a subsidiary of Fountainhead Capital Management Limited.
www.vycormedical.comRecent News: VYCO
View MorePerformance Overview: VYCO
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VYCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VYCO
View MoreValuation Measures
Market Cap
3.27M
Enterprise Value
4.20M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.22
Price/Book (mrq)
--
Enterprise Value/Revenue
2.91
Enterprise Value/EBITDA
63.34
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--